Zurich, (ots) - Solianis' multisensor system for non-invasive
Continuous Glucose Monitoring is currently being tested by diabetic
patients in the home and work environment. 12 patients have completed
a 10-day trial aimed at assessing system reliability. Results
indicate that the system tracks glucose in home-use settings and is
sensitive to hypoglycemic glucose excursions.
With this proof of concept Solianis can now proceed to producing
the final prototype. The company expects to launch its first product
in Europe in 2010 after CE approval, targeting this non-invasive
device at the insulin dependent diabetes population. Later model
variants will address patients with diabetes and impaired glucose
Solianis is also announcing that Barry W. Wilson, former Medtronic
President International, will join Solianis Business Advisory Board.
He has 40 years experience in the life science business and will be a
valuable addition to the Solianis team. With the promising trial
results and the valuable support of Barry Wilson, we are confident
that we can introduce our first generation non-invasive Continuous
Glucose Monitor in 2010, said Mario Stark, the CEO of Solianis.
Solianis Monitoring AG is a medical devices company developing a
non-invasive Continuous Glucose Monitor (CGM) for self-monitoring
patients with diabetes. Its technology is based on a unique and
proprietary multisensor technology for monitoring physiological
parameters. It was incorporated in May 2005, and is funded by private
investors and the pioneer fund of the Cantonal Bank of Zürich. The
Solianis non-invasive device delivers comparable results to the
currently FDA-approved minimally invasive devices.
ots Originaltext: Solianis Monitoring AG
Mario Stark, CEO